Avalyn Pharma Inc. Common Stock (AVLN) - Total Liabilities
Based on the latest financial reports, Avalyn Pharma Inc. Common Stock (AVLN) has total liabilities worth $27.10 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See AVLN cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Avalyn Pharma Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Avalyn Pharma Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check AVLN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Avalyn Pharma Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Avalyn Pharma Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yelp Inc
NYSE:YELP
|
USA | $256.73 Million |
|
Anhui Expressway Company Limited
F:HU7
|
Germany | €16.76 Billion |
|
Zimplats Holdings Ltd
AU:ZIM
|
Australia | AU$813.69 Million |
|
G-III Apparel Group Ltd
NASDAQ:GIII
|
USA | $850.50 Million |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩319.38 Billion |
|
Securitize Corp.
NYSE:SECZ
|
USA | $283.77 Million |
|
Guangdong CHJ Industry Co Ltd
SHE:002345
|
China | CN¥3.32 Billion |
|
Nantong Jiangshan Agrochemical & Chemicals Co Ltd
SHG:600389
|
China | CN¥5.07 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Avalyn Pharma Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AVLN total asset value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 33.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avalyn Pharma Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avalyn Pharma Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Avalyn Pharma Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $387.54 Million | +29.59% |
| 2024-12-31 | $299.04 Million | -- |
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled fo… Read more